Blog

Vivek Subbiah: Pleased to host a podcast interview with Roni Shouval on Secondary T-Cell Malignancies Following CAR T-Cell Therapy

Photo taken from Vivek Subbiah/LinkedIn

Apr 21, 2024, 18:22

Vivek Subbiah: Pleased to host a podcast interview with Roni Shouval on Secondary T-Cell Malignancies Following CAR T-Cell Therapy

Vivek Subbiah shared a post on X:

“Secondary T-Cell Malignancies Following Chimeric antigen receptor (CAR) T-Cell Therapy have been reported recently. Pleased to host a podcast interview with Roni Shouval, author of a paper on this topic published in JAMA Oncology, Hosted on AMA Ed Hub.”

Additional information
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.

About OncoDaily

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.